Free tool
FAERS Monitor: Valcyte
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022257 or its brand name (Valcyte, Valganciclovir Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
19,081
Serious
17,710
93% of reports
Hospitalization
9,377
Death reported
3,264
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use3,071
- cytomegalovirus infection1,840
- drug ineffective1,540
- neutropenia1,189
- pyrexia967
- leukopenia960
- diarrhoea952
- acute kidney injury862
- cytomegalovirus viraemia770
- death762
- pancytopenia717
- drug resistance683
- anaemia677
- transplant rejection644
- thrombocytopenia640
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 83 |
| 2005 | 143 |
| 2006 | 102 |
| 2007 | 115 |
| 2008 | 144 |
| 2009 | 159 |
| 2010 | 175 |
| 2011 | 409 |
| 2012 | 518 |
| 2013 | 413 |
| 2014 | 513 |
| 2015 | 555 |
| 2016 | 608 |
| 2017 | 1,078 |
| 2018 | 1,375 |
| 2019 | 1,683 |
| 2020 | 1,823 |
| 2021 | 1,563 |
| 2022 | 1,563 |
| 2023 | 1,673 |
| 2024 | 1,891 |
| 2025 | 1,509 |
| 2026 | 986 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,078 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytomegalovirus viraemiaSignal | 770 | 230.5 | 213.5 | 145,352 |
| cytomegalovirus infectionSignal | 1,840 | 137.1 | 130.9 | 221,131 |
| transplant rejectionSignal | 644 | 96.2 | 88.9 | 55,750 |
| drug resistanceSignal | 683 | 30.1 | 27.9 | 18,687 |
| leukopeniaSignal | 960 | 21.5 | 20.2 | 18,475 |
| pancytopeniaSignal | 717 | 14.3 | 13.3 | 8,775 |
| neutropeniaSignal | 1,189 | 9.7 | 9.2 | 9,266 |
| thrombocytopeniaSignal | 640 | 6.3 | 5.9 | 2,872 |
| acute kidney injurySignal | 862 | 6.2 | 5.8 | 3,793 |
| anaemiaSignal | 677 | 3.9 | 3.6 | 1,480 |
| off label useSignal | 3,071 | 3.9 | 3.8 | 6,811 |
| pyrexiaSignal | 967 | 3.1 | 2.9 | 1,381 |
| diarrhoea | 952 | 1.6 | 1.5 | 236 |
| drug ineffective | 1,540 | 1.3 | 1.2 | 106 |
| death | 762 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.